Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label pharmacokinetics study of radiolabeled bendamustine in relapsed or refractory malignancy
NL-OMON33657Not yet recruiting
- Sponsor
- Cephalon, Inc.
- Start
- Nov 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of bendamustine in cancer, hematopoietic malignancies and Nonhematologic neoplasms, sponsored by Cephalon, Inc. Primary endpoints: Pharmacokinetics of [14C]bendamustine and metabolites, Total radioactivity in blood and plasma and 1 more. Planned start Nov 2008; status: not yet recruiting.
02
Drugs
bendamustine
03
Conditions
cancerhematopoietic malignanciesNonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON33657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33657.